Carl Gordon is a founding managing partner and co-head of global private equity with OrbiMed. He is also a founding general partner and co-head of private equity at The Biotech Growth Trust, also serving as a portfolio manager for the firm. He is active in both private equity and small-capitalisation public equity investments.
He has been listed on the Forbes Midas List for the past six years, ranking at number 14 in 2019.
In the past year, three of his investments have experienced strong exits. ARMO Biosciences was acquired by Eli Lilly for $1.6 billion, while Alector and Constellation both went public. Other investments of his have also experienced much success in recent years, such as the sale of True North Therapeutics to Bioverativ for up to $825 million and Seragon Pharmaceuticals to Roche for up to $1.7 billion.
According to Forbes, a few of his newer investments include Passage Bio, Terns Pharmaceuticals and Star Therapeutics.
Carl is currently on the board of directors for Seragon Pharmaceuticals, SpringWorks Therapeutics, Good Start Genetics, Adicet Bio, Adimab, True North Therapeutics, Protometrix, Amnis Corporation, Agensys, Aragon Pharmaceuticals, ORIC Pharmaceuticals, Singulex and Turning Point Therapeutics.
After completing his post-doctoral fellowship, he was a senior biotechnology analyst at Mehta and Isaly.
Carl received a PhD in molecular biology from the Massachusetts Institute of Technology and a bachelor’s from Harvard College. He completed a post-doctoral fellowship at Rockefeller University. Carl also holds a Certified Financial Analyst designation.Tags: biotechnology, VC